Mast cell activation syndrome (MCAS) affects more than 15% of the U.S. population but evades most practitioners’ radar. Just five years ago, it wasn’t even on my radar, despite already having 20 years of experience as a clinician at that time. The more I dug (similar to leaky gut and post-COVID syndrome), the more I found my patients were suffering from this disorder.
Michelle Shine, PhD
Michelle Shine serves as a biomedical scientist in the hemp industry. She has worked on the cutting edge of biotechnology, and has published peer-reviewed articles in the fields of stem cell therapy, tissue engineering, and more. You may email Michelle at Michelle@HempMagik.com.